A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
← catalyst calendarNCT07280377 · readout in 344 d
Sponsored by Oncolytics Biotech (industry) · ONCY — their whole pipeline →. With Crolll Gmbh, AIO-Studien-gGmbH.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
122estimated
Sites
15
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-27 | actual | When the study began enrolling |
| Primary completion | 2027-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Anal Cancer Metastatic
- Squamous Cell Carcinoma of the Anus Stage Unspecified
- Pancreatic Cancer Metastatic
- Unresectable Pancreatic Carcinoma
Interventions
- Drug: Pelareorep
- Drug: Atezolizumab — also filed as Tecentriq
- Drug: Gemcitabine and nab-paclitaxel — also filed as Gemzar, Abraxane
- Drug: Trifluridine Tipiracil — also filed as Lonsurf
- Drug: mFOLFIRINOX Treatment Regimen
Primary outcomes
what the primary-completion date above is the date OFOverall Response Rate (ORR) for Cohort 1, 2, 4, and 5
measured At week 16 (within each cohort)
Disease Control Rate (DCR) - Cohort 3
measured at week 16
Overall Survival (OS) - Cohort 5
measured Cohort 5: From the date of randomization through long term follow up at 2 years
Permalink · ONCY's whole pipeline · Catalyst calendar · Every registered study · What changed